caa a22 4500 606239774 CHVBK 20210128101304.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s00508-014-0692-4 doi (NATIONALLICENCE)springer-10.1007/s00508-014-0692-4 N-acetylcysteine in patients with COPD exacerbations associated with increased sputum [Elektronische Daten] [Zeynep Ayfer Aytemur, Aysegul Baysak, Ozer Ozdemir, Timur Köse, Abdullah Sayiner] N-Acetylcystein bei Patienten mit Exazerbation einer COPD mit erhöhter Sputumproduktion Summary: Background: N-acetylcysteine (NAC) has been shown not to alter the clinical outcome in chronic obstructive pulmonary disease (COPD) exacerbations. However, NAC may improve symptoms through its mucolytic effect in the subgroup of patients with increased sputum production. The aims of this study were to determine whether NAC improves symptoms and pulmonary function in patients with COPD exacerbation and increased sputum production. Methods: This was a placebo-controlled study, where patients with severe COPD and increased sputum production, who were hospitalized for an exacerbation, were included. They were randomized to receive either NAC 200mg tid or placebo in addition to the usual treatment. Results: Forty-two patients were included and were equally distributed to NAC and placebo groups. The symptoms, namely, ease of sputum production and dyspnea at rest and on exertion significantly improved in both groups; but there was no difference in improvement between NAC and placebo groups (p = 0.96, 0.62, 0.31, respectively). Similarly, forced expiratory volume-one second (FEV1) and PaO2 levels improved significantly in NAC (964 ± 599-1239 ± 543ml, p < 0.001, and 57.5 ± 14.5-70.5 ± 16.0mmHg, p < 0.001, respectively) and placebo groups (981 ± 514-1180 ± 535ml, p < 0.001 and 57.9 ± 14.3-68.7 ± 19.0mmHg, p < 0.001, respectively), without any difference between the two groups (p = 0.52 and 0.57). There was no difference in the number of exacerbations during the 6-month follow-up period. Conclusion: NAC does not have any beneficial effect on clinical outcomes in patients with severe COPD exacerbation associated with increased and/or viscous mucus production. Springer-Verlag Wien, 2014 Chronic obstructive pulmonary disease nationallicence Exacerbation nationallicence Treatment nationallicence N-Acetylcysteine nationallicence Mucolytic nationallicence Chronisch obstruktive Lungenerkrankung nationallicence Exazerbation nationallicence Behandlung nationallicence N-Acetylcystein nationallicence Schleimlösend nationallicence Ayfer Aytemur Zeynep Department of Chest Diseases, Inonu University Faculty of Medicine, Malatya, Turkey aut Baysak Aysegul Department of Chest Diseases, Izmir University Faculty of Medicine, Izmir, Turkey aut Ozdemir Ozer Siverek State Hospital, Sanliurfa, Turkey aut Köse Timur Department of Medical Informatics and Biostatistics, Ege University Faculty of Medicine, Izmir, Turkey aut Sayiner Abdullah Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey aut Wiener klinische Wochenschrift Springer Vienna 127/7-8(2015-04-01), 256-261 0043-5325 127:7-8<256 2015 127 508 https://doi.org/10.1007/s00508-014-0692-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-014-0692-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ayfer Aytemur Zeynep Department of Chest Diseases, Inonu University Faculty of Medicine, Malatya, Turkey aut NATIONALLICENCE 700 1- Baysak Aysegul Department of Chest Diseases, Izmir University Faculty of Medicine, Izmir, Turkey aut NATIONALLICENCE 700 1- Ozdemir Ozer Siverek State Hospital, Sanliurfa, Turkey aut NATIONALLICENCE 700 1- Köse Timur Department of Medical Informatics and Biostatistics, Ege University Faculty of Medicine, Izmir, Turkey aut NATIONALLICENCE 700 1- Sayiner Abdullah Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/7-8(2015-04-01), 256-261 0043-5325 127:7-8<256 2015 127 508